Jeffrey Wade Net Worth

The estimated Net Worth of Jeffrey L Wade is at least $2.23 Million dollars as of 28 February 2024. Mr. Wade owns over 97,564 units of Lexicon Pharmaceuticals Inc stock worth over $611,619 and over the last 17 years he sold LXRX stock worth over $0. In addition, he makes $1,614,320 as Chief Financial Officer and Executive Vice President - Corporate and Administrative Affairs at Lexicon Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Wade LXRX stock SEC Form 4 insiders trading

Jeffrey has made over 8 trades of the Lexicon Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 97,564 units of LXRX stock worth $164,883 on 28 February 2024.

The largest trade he's ever made was exercising 97,564 units of Lexicon Pharmaceuticals Inc stock on 28 February 2024 worth over $164,883. On average, Jeffrey trades about 9,938 units every 60 days since 2008. As of 28 February 2024 he still owns at least 361,905 units of Lexicon Pharmaceuticals Inc stock.

You can see the complete history of Mr. Wade stock trades at the bottom of the page.

Jeffrey Wade biography

Jeffrey L. Wade J.D. serves as Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs of the Company. He has been our executive vice president, corporate and administrative affairs and chief financial officer since February 2015 and previously served in a series of finance and legal leadership positions since joining our company in 1999. Mr. Wade was previously a corporate securities and finance attorney for ten years with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries. Mr. Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute. He received his B.A. and J.D. from the University of Texas.

What is the salary of Jeffrey Wade?

As the Chief Financial Officer and Executive Vice President - Corporate and Administrative Affairs of Lexicon Pharmaceuticals Inc, the total compensation of Jeffrey Wade at Lexicon Pharmaceuticals Inc is $1,614,320. There are 2 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.

How old is Jeffrey Wade?

Jeffrey Wade is 55, he's been the Chief Financial Officer and Executive Vice President - Corporate and Administrative Affairs of Lexicon Pharmaceuticals Inc since 2015. There are 16 older and 2 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.

What's Jeffrey Wade's mailing address?

Jeffrey's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.

Insiders trading at Lexicon Pharmaceuticals Inc

Over the last 17 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc..., and Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.

What does Lexicon Pharmaceuticals Inc do?

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Complete history of Mr. Wade stock trades at Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc executives and stock owners

Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Lonnel Coats,
  President, Chief Executive Officer, Director
• Praveen Tyle,
  Executive Vice President - Research and Development
• Jeffrey Wade,
  Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Lonnel Coats,
  CEO & Director
• Alan Main,
  Executive Vice President, Commercial Supply Operations
• Jeffrey L. Wade J.D.,
  Pres & CFO
• Dr. Alan J. Main Ph.D.,
  Exec. VP of Innovation & Chemical Sciences
• Dr. Alan J. Main,
  Exec. VP of Innovation & Chemical Sciences
• Brian T. Crum,
  VP, Gen. Counsel & Sec.
• James Tessmer,
  Vice President - Finance and Accounting
• Raymond Debbane,
  Independent Chairman of the Board
• Samuel Barker,
  Independent Director
• Frank Palantoni,
  Independent Director
• Judith Swain,
  Independent Director
• Philippe Amouyal,
  Independent Director
• Robert Lefkowitz,
  Independent Director
• Christopher Sobecki,
  Independent Director
• Alan Nies,
  Independent Director
• Dr. Robert J. Lefkowitz,
  Consultant & Independent Director
• Brian Crum,
  Vice President, General Counsel
• Dr. Craig B. Granowitz M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kristen L. Alexander,
  VP of Fin. & Accounting
• Chas Schultz,
  Exec. Director of Corp. Communications & Patient Advocacy
• Sam L Barker,
  Director
• Alexander A Santini,
  EVP and CCO
• Pablo Lapuerta,
  EVP and CMO
• International S.C.A.Wittouc...,
  
• Us Partners Llc Ulys, L.L.C...,
  
• Tamar D Howson,
  EVP of Bus Dev
• Barry Mills,
  Director
• Julia P Gregory,
  EVP and CFO
• James R Phd Piggott,
  SVP of Pharm Bio
• Lance K Ishimoto,
  SVP, Intellectual Property
• Clayton Stuart Rose,
  Director
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Artal ...,
  
• International S.C.A.Minne P...,
  
• Diane E. Sullivan,
  Director
• Thomas Garner,
  SVP, Chief Commercial Officer
• Arthur T Sands,
  Pres & CEO
• John Northcott,
  VP, Marketing, Comm Strategy
• Cv Ulys, L.L.C.Debbane Raym...,
  
• International S.C.A.Minne P...,
  
• Brian P Zambrowicz,
  EVP, Chief Scientific Officer
• Llc Invus, L.P.Invus Public...,
  
• International S.C.A.Invus, ...,
  
• Kathleen M Wiltsey,
  Director
• Llc Invus, L.P.Invus Adviso...,
  
• Philip M Brown,
  SVP Clinical Development
• Steven Alan Tragash,
  VP, Corporate Affairs
• Llc Invus, L.P.Invus Adviso...,
  
• Ajay Bansal,
  EVP Corp Dev and CFO
• Kristen Alexander,
  VP, Finance and Accounting
• C.V. Invus,
  Director
• Craig B Granowitz,
  SVP, Chief Medical Officer
• Kenneth B. Kassler Taub,
  SVP, Regulatory & QA
• Wendy Mc Dermott,
  VP, Human Resources
• Kiernan Seth,
  VP, Chief Commercial Officer
• Michael Exton,
  Chief Executive Officer
• Brian Corrigan,
  SVP, Regulatory & QA